Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca And Ironwood Link Up To Bring Linaclotide To China

This article was originally published in PharmAsia News

Executive Summary

Ironwood has signed AstraZeneca as its partner to develop and commercialize the irritable bowel syndrome drug linaclotide in China, though a Phase III trial has yet to start; Ironwood also announced it will commercialize AstraZeneca’s Nexium in the U.S.

You may also be interested in...



Ironwood/Forest Talk Ballpark Pricing For Linzess, Gear Up For Q4 Launch

Locally-acting linaclotide wins FDA approval for two indications – chronic idiopathic constipation and constipation-predominant irritable bowel syndrome – with no limits on length of use, a development that could reinvigorate the GI space.

Ironwood Gears Up For Phase III China Linaclotide Trial; Eyes On South America And Other Emerging Markets

Taking an unusually global perspective for a clinical-stage biotech, Ironwood Pharmaceuticals has plans to undertake clinical trials of its lead gastrointestinal drug, linaclotide, in China, Brazil and other emerging markets, then seek regional partners.

Sarepta Files DMD Gene Therapy, Seeking An Accelerated Path To Market

The company is seeking FDA accelerated approval of the closely watched gene therapy based on a surrogate marker and has proposed its fully enrolled Phase III trial to serve as a confirmatory study.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC079633

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel